2022-01-202022-01-202009Eker, S. S. vd. (2009). "Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?". World Journal of Biological Psychiatry, 10(4), Part 2, 400-408.1562-2975https://doi.org/10.1080/15622970903131886https://www.tandfonline.com/doi/full/10.1080/15622970903131886http://hdl.handle.net/11452/24198Background. This study aims to investigate if there is a differential outcome of serotonergic and noradrenergic antidepressant treatment and if menopausal status has an impact on antidepressant response in depressed women. Methods. Data of the 111 depressed women who were included and completed the previous four open-label studies where patients were evaluated six times during a 10-week period, were pooled in the current study. Each of the reboxetine, sertraline and venlafaxine groups consisted of 37 depressed women. Patients were also divided into two subgroups of age, determining the 44 years as the cut-off point representing the menopausal status. Results. No significant difference was observed in the percent change of Hamilton Depression Rating Scale-17 (HDRS) and remission rates among treatment groups. Percent changes in Clinical Global Impression-Severity of Illness scale (CGI-S) and response rates were in favour of venlafaxine group at week 10. Individual HDRS items 2, 3, 4, 5 and 6 demonstrated significant improvement in the sertraline group, whereas HDRS item 7 demonstrated significant improvement in the venlafaxine group. An early reduction in anxiety subscale was observed in the venlafaxine group. Menopausal status had no impact on the outcome measures. Conclusions. These results suggest that noradrenergic and serotonergic activity do not differ from each other in treating depressed women. However, serotonergic activity appears to be more prominent in some particular symptoms such as feelings of guilt, suicidal ideation and sleep. Also, menopause does not appear to affect antidepressants' benefit in depressed women.eninfo:eu-repo/semantics/closedAccessAntidepressantsDepressionGenderNorepinephrine reuptake inhibitorGender-differencesSex-differencesPostmenopausal womenSelective serotoninDouble-blind5-hydroxytryptamine(2a) receptorsEstrogen replacement12-month prevalenceTreatment responsePsychiatryAdrenergic uptake inhibitorsAdultAge factorsAntidepressive agentsClimactericClinical trials as topicCyclohexanolsDepressive disorder, majorDrug therapy, combinationFemaleHumansMiddle agedMorpholinesPersonality inventoryRetrospective studiesSerotonin uptake inhibitorsSertralineYoung adultArticle0002730032000072-s2.0-77449098829400408104, Part 219670086PsychiatryDesvenlafaxine; Involutional Depression; AntidepressantsAlpha adrenergic receptor stimulating agentAntidepressant agentReboxetineSerotonin agonistSertralineVenlafaxineAdrenergic receptor affecting agentAntidepressant agentCyclohexanol derivativeMorpholine derivativeReboxetineSerotonin uptake inhibitorSertralineVenlafaxineAdultAgedArticleClinical Global Impression scaleControlled studyDepressionDrug dose increaseDrug efficacyDrug mechanismFemaleHamilton scaleHumanMajor clinical studyMenopauseRemissionAgeClimacteriumClinical trialComparative studyDrug combinationDrug effectMajor depressionMiddle agedPersonality testPsychological aspectRetrospective study